In a report released on April 17, Tim Anderson from Bank of America Securities reiterated a Buy rating on Gilead Sciences (GILD – Research Report), with a price target of $126.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Tim Anderson has given his Buy rating due to a combination of factors that highlight Gilead Sciences’ strong financial outlook and strategic positioning. The company’s long-term growth prospects appear robust, driven by its durable profit and loss profile, which is supported by minimal patent expirations until the early 2030s. This stability is further bolstered by the success of its anchor brand, Biktarvy, which contributes to Gilead’s reputation as a ‘beat and raise’ story.
Additionally, Gilead Sciences is perceived to have lower relative exposure to tariff risks and drug pricing pressures compared to its peers. This is attributed to its lesser reliance on transfer pricing and the relatively protected nature of the HIV market from payer pressures. These factors collectively support an above-average valuation multiple for Gilead, justifying the Buy rating with a price objective of $126.00 USD.
Anderson covers the Healthcare sector, focusing on stocks such as Gilead Sciences, Johnson & Johnson, and Eli Lilly & Co. According to TipRanks, Anderson has an average return of 8.8% and a 69.86% success rate on recommended stocks.
In another report released on April 17, BMO Capital also maintained a Buy rating on the stock with a $120.00 price target.